Abstract
Introduction Rapid and accurate detection of cytomegalovirus (CMV) infection and reactivation is crucial to preventing adverse outcomes in immunocompromised individuals, especially in transplant recipients. Current PCR-based assays were developed for use with plasma specimens, but CMV is present in bronchoalveolar lavage fluid (BAL) in immunocompromised patients with CMV pneumonia and has also been detected in cerebrospinal fluid (CSF).
Objectives We evaluated the performance of the Abbott Alinity m CMV assay compared to the Abbott RealTime CMV assay for quantification of CMV in plasma, BAL, and CSF specimens.
Methods Analytical performance, including linearity, precision, and limit of detection, was established for plasma, BAL, and CSF specimen types using reference CMV control material (SeraCare). To evaluate clinical performance, 190 plasma specimens, 78 BAL specimens, and 26 CSF specimens were tested with the Alinity m assay and compared to the RealTime CMV assay.
Results The Alinity m CMV assay showed high precision (SD <0.01 to 0.13) within the quantifiable range (1.49-8.00 log10 IU/mL) for all 3 specimen types, with strong clinical correlation to the RealTime CMV assay results (r2=0.9779 for plasma, r2=0.9373 for BAL, r2=0.9889 for CSF).
Conclusion The Alinity m CMV assay may be useful for rapid detection of CMV in plasma, BAL, and CSF specimens.
Competing Interest Statement
JK is an employee of Abbott Laboratories RL has received research support from Abbott Laboratories (reagents, supplies)
Funding Statement
This study was funded by Molecular Diagnostics of Abbott.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Kansas Health System waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding This study was funded by Molecular Diagnostics of Abbott.
Conflict of Interest Declaration Joshua Kostera is an employee of Abbott Laboratories
Rachael Liesman has received research support from Abbott Laboratories (reagents, supplies)
Data Availability
All data produced in the present study are available upon reasonable request to the authors